Özet:

Breast cancer (MK) is a cancer that is common in women and is the second most common cause of death. 3-8% of patients are diagnosed in metastatic stages, and 40% of patients develop metastatic stages. In the treatment of these patients, if there is no viral crisis or endocrine treatment resistance, endocrine treatment is recommended to prevent the connection of the estrogen hormone to the receptors or reduce the production of estrogen. Metastatics may not be provided in patients except in exceptional cases. In patients, symptoms should be controlled, the progression of the disease should be delayed and serious complications related to the progression of the disease should be prevented, the quality of life should be continued and the survival period should be extended. It is important for patients to choose whether they are in the pre-perimenoposis or menopausal period. Selective estrogen receptor modulators (Tamoxifen) in the pre-perimenoposal period, with over ablation/suppression in the postmenoposal period, can be used. In the postmenopausal period, Tamoksifen, Aromatase inhibitors: nonsteroidal (Letrozol or Anastrozol) and steroidal (Exemestan), estrogen receptor down regulator (Fulvestrant) are among the options. Combined therapies with targeted molecules such as cyclin-dependent kinase 4/6 inhibitors (Palbociclib, Ribociclib, Abemaciclib) and mTOR inhibitors (Everolimus), phosphotydil inositol 3 kinase inhibitors (Buparlisib) may also be applied in order to increase its effectiveness in the development of endocrine therapies. It also increases the effectiveness of the combinations of targeted treatments with endocrine treatments.

Anahtar Kelimeler: